Phase II Trial of Oral GLP-1 Agonist VCT220 for Obesity Shows Promise | Retatrutide News

A phase II trial of the oral nonpeptide GLP-1 receptor agonist VCT220 for obesity was reported in Nature. This study highlights the potential for oral G...
Clinical Trials · November 4, 2026